
Mesoblast Limited MESO
$ 10.9
-2.42%
Mesoblast Limited Interest Expense | MESO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Mesoblast Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.8 M | 20.7 M | 19.4 M | 16.9 M | 15.9 M | 14.7 M | 11.7 M | 1.83 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 M | 1.83 M | 15.4 M |
Quarterly Interest Expense Mesoblast Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.3 M | 21.8 M | 10.7 M | 20.7 M | 10.2 M | 19.4 M | 4.9 M | 4.9 M | 4.55 M | - | 4.3 M | 4.06 M | 4.14 M | - | 3.95 M | 3.99 M | 3.93 M | - | 3.73 M | 3.6 M | 3.58 M | 2.49 M | 3.14 M | 2.49 M | 2.65 M | - | 423 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.8 M | 423 K | 6.73 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amicus Therapeutics
FOLD
|
10.2 M | - | - | $ 4.47 B | ||
|
Frequency Therapeutics
FREQ
|
5.23 M | - | - | $ 528 M | ||
|
Galecto
GLTO
|
1.17 M | - | - | $ 762 M | ||
|
GlycoMimetics
GLYC
|
651 K | - | 9357.83 % | $ 1.01 B | ||
|
Graybug Vision
GRAY
|
268 K | - | -11.23 % | $ 9.65 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Happiness Biotech Group Limited
HAPP
|
263 K | - | 1.35 % | $ 17.8 M | ||
|
Novavax
NVAX
|
40.6 M | $ 7.47 | -3.24 % | $ 1.21 B | ||
|
Hepion Pharmaceuticals
HEPA
|
9.46 K | - | -18.79 % | $ 39.3 K | ||
|
Hoth Therapeutics
HOTH
|
27.1 K | - | - | $ 18.8 M | ||
|
IMARA
IMRA
|
-49 K | - | 15.96 % | $ 663 M | ||
|
KalVista Pharmaceuticals
KALV
|
8.56 M | - | - | $ 1.45 B | ||
|
KemPharm
KMPH
|
1.5 M | - | -0.34 % | $ 200 M | ||
|
Kezar Life Sciences
KZR
|
1.55 M | - | - | $ 53.3 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
9.16 K | - | - | $ 63.4 M | ||
|
Magenta Therapeutics
MGTA
|
-974 K | - | -7.74 % | $ 41.6 M | ||
|
NovaBay Pharmaceuticals
NBY
|
-20 K | - | - | $ 11.3 M | ||
|
NeuroBo Pharmaceuticals
NRBO
|
735 K | - | 0.43 % | $ 12 M | ||
|
OncoCyte Corporation
OCX
|
1.01 M | - | 17.22 % | $ 355 K | ||
|
Onconova Therapeutics
ONTX
|
478 K | - | -0.47 % | $ 21 M | ||
|
Opthea Limited
OPT
|
46.5 M | - | - | $ 1.2 B | ||
|
Verastem
VSTM
|
1.14 M | $ 6.33 | -7.8 % | $ 439 M | ||
|
BiomX
PHGE
|
-919 K | $ 1.85 | 14.2 % | $ 3.02 M | ||
|
Pieris Pharmaceuticals
PIRS
|
727 K | - | -15.58 % | $ 1.22 B | ||
|
Plus Therapeutics
PSTV
|
395 K | - | - | $ 301 M | ||
|
Pluristem Therapeutics
PSTI
|
476 K | - | -1.9 % | $ 33.3 M | ||
|
Qualigen Therapeutics
QLGN
|
988 K | - | 5.59 % | $ 1.16 M | ||
|
Qilian International Holding Group Limited
QLI
|
555 K | - | -6.08 % | $ 184 M | ||
|
Cassava Sciences
SAVA
|
-203 K | - | - | $ 110 M | ||
|
Selecta Biosciences
SELB
|
-2.01 M | - | -8.69 % | $ 126 M | ||
|
Sangamo Therapeutics
SGMO
|
-3.56 M | - | - | $ 50.4 M | ||
|
Sensei Biotherapeutics
SNSE
|
32 K | - | - | $ 17.5 M | ||
|
Sonnet BioTherapeutics Holdings
SONN
|
20.7 K | - | - | $ 826 K | ||
|
Synthetic Biologics
SYN
|
95 K | - | 1.32 % | $ 16.2 M | ||
|
Synlogic
SYBX
|
-2 K | - | - | $ 7.07 M | ||
|
Virios Therapeutics, LLC
VIRI
|
-6.07 M | - | 2710.01 % | $ 72.9 M | ||
|
Vallon Pharmaceuticals
VLON
|
250 K | - | -6.47 % | $ 5.76 M | ||
|
Vaxart
VXRT
|
-11 K | - | -25.06 % | $ 46.3 M | ||
|
XOMA Corporation
XOMA
|
12.2 M | - | - | $ 485 M | ||
|
Sesen Bio
SESN
|
296 K | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
-408 K | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
3.27 M | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
-3 K | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
-16 K | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
290 K | - | - | $ 13 M |